

tobacco control as part of the National Cancer Institute's (NCI's) Cancer Progress Report, and the Department of Health and Human Services' Healthy People 2010 Goals. It is also relevant to past reports of NCI plans for the National Investment in Cancer Research and NCI's long-term strategic plan for eliminating the suffering and death due to cancer. This survey is part of a continuing series of surveys that were sponsored by NCI and fielded periodically over the 1990's by the Census Bureau as part of the American Stop Smoking Intervention Study for

Cancer Prevention (ASSIST) project and made available for general public use. The Tobacco Use Supplements since 2001–02 have been fielded and will be continuing over the next decade alternating between a standard or core tobacco use survey (such as this 2006–2007 survey) and a special topic survey focusing on emerging adult tobacco control issues (such as the 2003 Tobacco Use Special Cessation Supplement). The survey will allow state specific estimates to be made. Data will be collected in May 2006, August 2006 and January 2007 from approximately

285,000 respondents. The National Cancer Institute is co-sponsoring this survey with the Centers for Disease Control and Prevention.

Frequency of Response: One-time study.

Affected Public: Individuals or households.

Type of Respondents: Persons 15 years of age or older. The annual reporting burden is presented in exhibit 1 below. There are no Capital Costs, Operating Costs and/or Maintenance Costs to report.

EXHIBIT 1.—ESTIMATES OF RESPONDENT HOUR BURDEN

Number of respondents (number of annual respondents)	Frequency of response	Average burden hours per response	Total hour burden (total annual hour burden)
285,000 (95,000)	1	0.1169	33,317 (11,106)

Request for Comments: Written comments and/or suggestions from the public and affected agencies should address one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) enhance the quality, utility and clarity of the information to be collected; and (4) minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Anne Hartman, M.S., M.A., Health Statistician, National Cancer Institute, Executive Plaza North—Suite 4005, 6130 Executive Blvd., MSC 7344, Bethesda, Maryland 20892–7344, or call non-toll free (301) 496–4970, or fax your request to (301) 435–3710, or e-mail your request, including your address, to ah42t@nih.gov or Anne_Hartman@nih.gov.

Comments Due Dates

Comments regarding this information collection are best assured of having

their full effect if received within 60 days of the date of this publication.

Dated: October 25, 2005.
Rachelle Ragland-Greene,
National Institutes of Health, NCI Project Clearance Liaison.
 [FR Doc. 05–21645 Filed 10–31–05; 8:45 am]
BILLING CODE 4101–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Submission for OMB Review; Comment Request; Assessment of the Use of Special Funding for Research on Type 1 Diabetes Provided by the Balanced Budget Act of 1997, the FY 2001 Consolidated Appropriations Act, and the Public Health Service Act Amendment for Diabetes

Summary: Under the provisions of section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below. This proposed information collection was previously published in the **Federal Register** on March 10, 2005, page 11994 and allowed 60 days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Institutes of Health may not conduct or sponsor, the respondent is not required to respond to, an information collection

that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

Proposed Collection

Title: Assessment of the Use of Special Funding for Research on Type 1 Diabetes Provided by the Balanced Budget Act of 1997, and the FY 2001 Consolidated Appropriations Act, and the Public Health Service Act Amendment for Diabetes. *Type of Information Collection Requested:* Revision, OMB control number: 0925–0503; expiration date: 06/30/2005. *Need and Use of Information Collection:* This survey will be one source of input into a statutorily mandated assessment and report to the Congress on special funding for research on type 1 diabetes provided by the Balanced Budget Act of 1997, (Pub. L. 105–33), the FY 2001 Consolidated Appropriations Act, (Pub. L. 106–554), and the Public Health Service Act Amendment for Diabetes, (Pub. L. 107–360). Collectively, these Acts provided \$1.14 billion in special funds to the Department of Health and Human Services (HHS) for research aimed at understanding, treating, and preventing type 1 diabetes and its complications. The Secretary of HHS subsequently designated to the NIDDK the lead responsibility in the Department for developing a process for allocation of these funds. The primary objective of this study is to gain information, via a brief questionnaire, from NIH research grantees who were the primary recipients of these special funds, concerning their views on the impact of the type 1 diabetes research

fundings with respect to: (1) Advancing scientific accomplishments involving innovative, clinically relevant, and multidisciplinary research on type 1 diabetes; (2) developing resources or reagents useful for type 1 diabetes research; and (3) increasing the number and quality of type 1 diabetes investigators. The responses will provide valuable information concerning how the funds have facilitated research as intended by these Acts of the Congress. The results will also help determine how research progress from these special congressional initiatives fits within the continuum of diabetes research, and how these funds have contributed to the field of type 1 diabetes research and NIH efforts to combat this challenging health problem. Information from this study will aid in evaluation of the process by which the research goals for use of the special type 1 diabetes funds have been developed and are being pursued. Responses already collected from this survey were analyzed as part of an interim program assessment that was published by the NIDDK in April, 2003 http://www.nidDK.nih.gov/federal/planning/type_1_specialfund/. This revised survey will contribute to a statutorily mandated report, due to the Congress on January 1, 2007, evaluating the process and efforts under this program and assessing research initiatives funded by these Act of Congress. *Frequency of Response:* The survey will require a one time response; though, respondents may be contacted again in the event of future congressionally mandated reports on the use of the special type 1 diabetes research funds. *Affected Public:* Research scientists who received the special funds about which the Congress has mandated in law the requirements for an evaluation report. *Type of Respondents:* Laboratory and clinical investigators who have received support from the special type 1 diabetes funds provided under the laws previously cited. The annual reporting burden is as follows: *Estimated number of respondents:* 500; *Estimated Number of Responses per Respondent:* 1; *Average Burden Hours per Response:* 1; and *Estimated Total Burden Hours Requested:* 500. The annualized total cost to respondents is estimated at: \$25,000. It is expected that the respondents will be contacted and will return their responses via electronic mail. These measures will reduce the burden on the respondents and the overall costs of administering the study. Respondents will be asked to answer no more than sixteen questions, one-third

of which will be answered with "yes" or "no" or a one-word response. There are no Capital Costs, Operating Costs or Maintenance Costs to report.

Request For Comments

Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

Direct Comments to OMB

Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, DC 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Dr. Shefa Gordon, Presidential Management Fellow, Office of Scientific Program and Policy analysis, NIDDK, NIH, Building 31, Room 9A31, 9000 Rockville Pike, Bethesda, MD 20892, or call non-toll-free number (301) 496-6623 or e-mail your request, including your address, to: gordonshefa@mail.nih.gov.

Comments Due Date

Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication.

Dated: October 19, 2005.

Barbara Merchant,

Executive Officer, NIDDK.

[FR Doc. 05-21649 Filed 10-31-05; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of Biotechnology Activities, Office of Science Policy, Office of the Director; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the second meeting of the National Science Advisory Board for Biosecurity (NSABB).

Under authority 42 U.S.C. 217a, Section 222 of the Public Health Service Act, as amended, the Department of Health and Human Services established NSABB to provide advice, guidance and leadership regarding federal oversight of dual-use research, defined as biological research with legitimate scientific purposes that could be misused to pose a biological threat to public health and/or national security.

The meeting will be open to the public, however, pre-registration is strongly recommended due to space limitations. Persons planning to attend should register online at <http://www.biosecurityboard.gov/meetings.asp> or by calling The Hill Group (Contact: A.J. Bownas) at 301-897-2789, ext. 100. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should indicate these requirements upon registration.

Name of Committee: National Science Advisory Board for Biosecurity.

Date: November 21, 2005.

Open: 9 a.m. to 6 p.m.

Agenda: Presentations and discussions regarding: (1) Criteria for defining dual-use research in the life sciences; (2) the role of a code of conduct for the life sciences; (3) communication of dual use research; (4) international perspectives on dual use research; (5) public comments; and (6) and other business of the Board.

Place: The National Institutes of Health, Building 31, 6C—Room 10, Bethesda, Maryland.

Contact Person: Allison Chamberlain, NSABB Program Assistant, 6705 Rockledge Drive, Bethesda, Maryland 20892, (301) 402-3090.

This meeting will also be webcast. The draft meeting agenda and other information about NSABB, including information about access to the webcast and pre-registration, will be available at <http://www.biosecurityboard.gov/meetings.asp>.

Any member of the public interested in presenting oral comments at the meeting may notify the Contact Person listed on this notice at least 10 days in advance of the meeting. Interested individuals and representatives of an organization may submit a letter of intent, a brief description of the organization